Lawrence Corey

Last updated
Lawrence Corey
Occupation(s)Immunologist, virologist

Lawrence Corey is an American immunologist and virologist who has done work in the development of antiviral therapies and vaccines, particularly for herpes simplex virus (HSV) and HIV/AIDS.

Contents

Education

Corey earned his MD from the University of Michigan, Ann Arbor in 1971. [1]

Research and career

In the early 1980s, Corey worked with biochemist and pharmacologist Dr. Gertrude Elion to demonstrate that an antiviral that was selective and specific for a viral-specified enzyme could be safely and effectively administered to control a chronic viral infection (herpes simplex virus type 2 or HSV-2). [ dubious – discuss ]

Corey first conceived of, demonstrated the core concepts of, and directed line association between quantitative viral load reduction and clinical benefit using topical, intravenous, and oral formulations of acyclovir in classic studies performed between 1980 and 1984. [2] [3] [4] Acyclovir was the first antiviral drug to get rapid approval from the FDA, and it was Corey's studies that defined its use in genital herpes. These studies led to the licensure for acyclovir in a wide variety of infections such as HSV-1, HSV-2, and varicella chickenpox virus, including the first use of an antiviral for daily long-term use. Acyclovir and its derivatives valacyclovir and famciclovir are the most prescribed antivirals in the world: over 400 million people have HSV-2 infection. These early studies prompted the subsequent successful involvement of the pharmaceutical and medical sciences communities to develop effective antiviral therapy for HIV and Hepatitis B.

In 1987, Corey directed the NIH-supported AIDS Clinical Trials Group (ACTG), which was established to test antivirals to HIV-1, and conducted pivotal clinical trials demonstrating the use of the antiretroviral drug AZT to reduce maternal-fetal transmission of HIV and the usefulness of combinations of antiretrovirals to prolong survival from HIV. [5] During this time, that laboratory demonstrated that HIV circulated in plasma well before the development of AIDS. [6] The ACTG subsequently showed that the initiation of therapy early during asymptomatic stages of HIV infection reduced progression to HIV, [7] and that combinations of antiretrovirals (3>2>1 drug) were critical to the control of HIV replication and management; the result being that HIV control has enabled life expectancy to increase globally. [8] Triple combination therapy with two nucleosides and a protease inhibitor demonstrated a marked reduction in viral load, increase in CD4+ T-cell count, and lowering of activation markers with the addition of the protease inhibitor. [9] The ACTG was the first to lead the integration of community members into clinical research activities. [10]

In the mid-1990s, Corey focused his work in the area of vaccine development, and in 1998 worked with the US National Institute of Allergy and Infectious Diseases to develop a global clinical trials group to speed the development of HIV vaccines. In 2002, Corey became a major driver in conceiving the Global HIV Vaccine Enterprise. The Enterprise is one of the few scientific programs that is overseen by leaders of the major industrialized countries of the world.

One of Corey's major scientific initiatives has been to study and develop better therapy for the treatment and prevention of infectious disease associated cancers such as Kaposi sarcoma and Burkitt lymphoma. [11] In the mid-2000s, Corey launched a partnership between Fred Hutchinson Cancer Research Center and the Uganda Cancer Institute. [12] On July 30, 2010, Dr. Corey was named the fourth president of the Fred Hutchinson Cancer Research Center. [13] One of his major initiatives was to increase the strength of the Fred Hutch's translational research programs and its commitment to bring better therapies and preventions for cancer to the developing world. In May 2015, the Fred Hutch/UCI partnership led to the opening of the first comprehensive cancer center jointly constructed by the US and African institutions in sub-Saharan Africa: the UCI-Fred Hutch Cancer Centre. [14] In 2013, as an outgrowth of his work in T-cell immunology, Corey became a cofounder of Juno Therapeutics, a company devoted to using genetically engineered T cells to fight cancer. [15]

Corey's early research dealt with herpes simplex viruses, and he headed several studies defining the disease and leading the licensure of acyclovir and valacyclovir for its treatment. [16] [17] This included a study to reduce acquisition among sexual partners. Between 1988 and 1998, Corey published a series of key studies showing the association between infection with HSV-2 and HIV-1. [18] [19] These studies led to pilot and large-scale clinical trials of anti-HSV-2 therapy to reduce HIV acquisition and transmission. [20] In 2000, Corey conducted the first discordant couple study using antiviral therapy for HSV-2. His publication in 2004 on reduction of transmission of HSV-2 was the first to demonstrate that antivirals could reduce transmission of infections to others (treatment as prevention), [21] a concept subsequently utilized by the HPTN 052 protocol team using continuous ART to reduce transmission of HIV to discordant couples. This latter approach is one of the current cornerstones of public health practices for reducing the morbidity and potentially the transmission of HIV-I. [22]

His research group showed the importance of the mucosal immune system in controlling HSV reactivation, leading to the current momentum to try to develop novel vaccines for treating genital herpes.[ citation needed ] Previously, the scientific consensus for HSV-2 pathogenesis was that virus reactivation was infrequent and determined by virus-neuronal interactions at the ganglion level and that most reactivations resulted in genital lesions.[ citation needed ]

Corey has a major contribution to the field of HIV vaccine development. The HIV Vaccine Trials Network (HVTN) now includes investigators on five continents spanning more than 30 cities [23] and is leading the research for phase 1–3 clinical trials of candidate HIV vaccines globally. The HVTN as of 2018 is conducting 4 large-scale efficacy trials in North America, South America, and several countries in sub-Saharan Africa.

On December 1, 2015, the work of Corey and HTVN scientists pursuing a vaccine to potentially halt HIV and AIDS was highlighted in an HBO/VICE special report titled "Countdown to Zero." [24]

Honors

Corey was a member of the editorial board of the New England Journal of Medicine. He is a fellow of the Infectious Diseases Society of America and a member of the American Epidemiological Society, the American Society for Clinical Investigation, and the Association of American Physicians. In addition, he is the recipient of the Pan American Society's Clinical Virology Award, the American Sexually Transmitted Diseases Association's Parran Award, and the University of Michigan Medical School's Distinguished Alumnus Award. [25] In 2008, he was elected to the National Academy of Medicine; likewise, in 2012, he was elected a Member of the American Academy of Arts and Sciences. He has published over 900 scientific publications and editorials as of 2018.

Selected works

References

  1. ↑ "Larry Corey, MD". Fred Hutch. Retrieved 2025-02-16.
  2. ↑ Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes simplex infections. N Engl J Med 1982;306:1313-19.
  3. ↑ Corey L, Fife KH, Benedetti JK, Winter C, Fahnlander A, Connor JD, Hintz MA, Holmes KK. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med. 1983;98:914-21.
  4. ↑ Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, Fahnlander A, Remington M, Winter C, Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310:1551-56.
  5. ↑ "What Will it Take to Achieve an AIDS-free World?". The Lancet.
  6. ↑ Coombs RW, Collier AC, Allain J-P, Nikora B, Leuther M, Gjerset GF, Corey L. Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989;321:1626-31.
  7. ↑ Volberding PA, Lagakos SW, Koch MA, Petinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, Hardy WD, Soeiro R, Fischl MA, Bartlett JG, Merigan TC, Hyslop NE, Richman DD, Valentine FT, Corey L, and the ACTG. Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection — A Controlled Trial in Persons with Fewer Than 500 CD4-Positive Cells per Cubic Millimeter. N Engl J Med. 1990 Apr 5;322(14):941-9.
  8. ↑ Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG, Henrard DR, Weller S, Corey L. Combination therapy with zidovudine and didanosine compared to zidovudine alone in HIV-1 infection. Ann Intern Med. 1993 Oct 15;119(8):786-93.
  9. ↑ Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L and the AIDS Clinical Trials Group. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996 Apr 18;334(16):1011-7.
  10. ↑ "History of the ACTG".
  11. ↑ "Part IV: The Infectious Connection". PRI.
  12. ↑ "The Hutch, Uganda get creative in cancer fight". Seattle Times.
  13. ↑ "Past Presidents & Directors".
  14. ↑ "Fred Hutch broadens global reach with Uganda cancer center". Puget Sound Business Journal.
  15. ↑ "New cancer research startup Juno Therapeutics raises $134M to push total funding past $300M". geekwire.com.
  16. ↑ Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med. 1982 Jun 3;306(22):1313-9.
  17. ↑ Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, Fahnlander A, Remington M, Winter C, Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984 Jun 14;310(24):1551-6.
  18. ↑ Stamm WE, Handsfield HH, Rompalo AM, Ashley RL, Roberts PL, Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA. 1988 Sep 9;260(10):1429-33.
  19. ↑ Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA. 1998 Jul 1;280(1):61-6.
  20. ↑ Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-799.
  21. ↑ Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM, Paavonen J, Ashley Morrow R, Beutner KR, Stratchounsky LS, Keene ON, Watson HA, Tait D, Vargas-Cortez M, for the Valacyclovir HSV Transmission Study Group. Once daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004 Jan 1;350(1):11-20.
  22. ↑ Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.
  23. ↑ "An HIV vaccine: the world's best long-term hope for ending AIDS". vaccinenews.net.
  24. ↑ "Larry Corey, xconomy.com".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.